On May 7, 2018 TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, reported that its President and CEO, Peter Hoang, will give a company presentation at the 2018 NYC Oncology Investor Conference, held May 8-9, 2018 at Wilson Sonsini Goodrich & Rosati in New York City (Press release, TapImmune, MAY 7, 2018, View Source [SID1234526174]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Date: Wednesday, May 9th, 2018

Time: 3:00 PM ET